8-K: Cadrenal Therapeutics Announces Full Year 2024 Results and Outlines Path for Tecarfarin Clinical Advancement

Cadrenal Therapeutics reports its full year 2024 results, highlighting a collaboration with Abbott and progress in the clinical development of tecarfarin.

Summary

• Cadrenal Therapeutics reported its full year 2024 financial results and provided an update on the clinical advancement of tecarfarin.
• The company's net loss for 2024 was $10.7 million, compared to $8.4 million in 2023.
• Research and development expenses were $4.2 million in 2024, slightly higher than $4.1 million in 2023.
• General and administrative expenses increased to $6.8 million in 2024 from $3.5 million in 2023.
• Cadrenal's cash and cash equivalents totaled $10.0 million as of December 31, 2024, compared to $8.4 million the previous year.
• The company raised approximately $9.8 million in financing during 2024.
• A collaboration agreement was established with Abbott to support the TECH-LVAD trial.
• The FDA provided additional guidance on the Phase 3 trial design for tecarfarin following a Type D meeting.
• Cadrenal appointed a new Chief Medical Officer and Chief Operating Officer.
• The company completed operational readiness activities to supply clinical trial materials.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a larger net loss, it also secured a significant collaboration with Abbott and made progress in clinical development. The focus on unmet needs and strategic partnerships is encouraging, but the financial losses temper the overall outlook.

Positives

• Cadrenal secured a collaboration agreement with Abbott to support the TECH-LVAD trial.
• The FDA provided additional guidance on the Phase 3 trial design for tecarfarin.
• Cadrenal appointed experienced executives to key leadership positions.
• The company successfully raised $9.8 million in financing during the year.
• Cadrenal received FDA Orphan Drug Designation for tecarfarin for LVAD patients.
• Cash and cash equivalents increased from $8.4 million to $10.0 million year over year.

Negatives

• Cadrenal reported a net loss of $10.7 million for the year ended December 31, 2024, which is higher than the $8.4 million loss in 2023.
• General and administrative expenses increased significantly from $3.5 million in 2023 to $6.8 million in 2024.

Risks

• The success of the TECH-LVAD trial and the approval of tecarfarin are subject to regulatory review and clinical trial outcomes.
• The company's ability to secure additional funding and partnerships is crucial for advancing its clinical pipeline.
• The forward-looking statements are subject to various important factors, including the ability to utilize Abbotts expertise to advance tecarfarin, the ability to successfully collaborate with Abbott, the initiation of the pivotal clinical trial for tecarfarin in LVAD patients by Cadrenal; for Cadrenal to provide improved patients outcomes and efficacy and safety for LVAD patients; the ability of Cadrenal to build a pipeline of specialized cardiovascular therapeutics and the other risk factors described in the Companys Annual Report on Form 10-K for the year ended December 31, 2024, and the Companys subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

Future Outlook

Cadrenal's primary focus in 2025 is on executing the assessment of tecarfarin's efficacy and safety in patients with LVADs and considering other areas of unmet need.

Management Comments

• Quang X. Pham, Chairman & CEO, stated that 2024 was a year of focus and laying the foundations for advancing tecarfarin into Phase 3 clinical development.
• Quang X. Pham also mentioned that the company has made strong progress on the partnering, regulatory, and financing fronts.

Industry Context

Cadrenal is focused on addressing unmet needs in anticoagulation therapy, particularly for patients with rare cardiovascular conditions. The collaboration with Abbott, a major player in the cardiovascular device market, suggests a strategic move to leverage expertise and resources in the LVAD space.

Comparison to Industry Standards

• Tecarfarin is being developed as a safer alternative to warfarin, which is currently used off-label for several rare cardiovascular conditions but has significant side effects.
• The collaboration with Abbott, specifically leveraging insights from HeartMate 3 clinical trials, indicates a focus on competing with existing LVAD therapies and improving patient outcomes.
• Other companies in the anticoagulation space include Bristol Myers Squibb (Eliquis), Johnson & Johnson (Xarelto), and Boehringer Ingelheim (Pradaxa), but Cadrenal is focusing on niche indications with unmet needs.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and clinical development progress will impact shareholder value.
• Patients: Successful development of tecarfarin could provide a safer alternative to warfarin for patients with rare cardiovascular conditions.
• Employees: The company's growth and clinical development activities will impact employees.
• Healthcare Professionals: The company will collaborate with anticoagulation therapy thought leaders and 15,000 healthcare professionals to improve anticoagulation outcomes for patients globally.

Next Steps

• Assessing the efficacy and safety of tecarfarin in patients with left ventricular assist devices (LVAD).
• Providing a full study design synopsis and detailed clinical trial design to the FDA for review.
• Exploring collaboration with potential development partners to advance tecarfarins pivotal clinical trial for patients with LVAD and other rare cardiovascular conditions.
• Advancing the Companys clinical pipeline.

Key Dates